1. Home
  2. SSTK vs MNPR Comparison

SSTK vs MNPR Comparison

Compare SSTK & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shutterstock Inc.

SSTK

Shutterstock Inc.

HOLD

Current Price

$9.85

Market Cap

570.9M

Sector

Technology

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$96.71

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSTK
MNPR
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
570.9M
587.4M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
SSTK
MNPR
Price
$9.85
$96.71
Analyst Decision
Buy
Strong Buy
Analyst Count
2
11
Target Price
$25.00
$107.00
AVG Volume (30 Days)
643.0K
144.8K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
8.61%
N/A
EPS Growth
23.76
54.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.43
$29.18
52 Week High
$29.50
$105.00

Technical Indicators

Market Signals
Indicator
SSTK
MNPR
Relative Strength Index (RSI) 27.75 82.98
Support Level N/A $52.92
Resistance Level $17.60 $103.17
Average True Range (ATR) 0.82 6.06
MACD -0.30 2.79
Stochastic Oscillator 5.75 91.97

Price Performance

Historical Comparison
SSTK
MNPR

About SSTK Shutterstock Inc.

Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: